Pivotal data supports U.S. FDA De Novo clearance and sets the stage for U.S. launch GALWAY, Ireland--(BUSINESS WIRE)-- Signum Surgical, a medical technology company dedicated to advancing the ...
Study finds 100 percent target lesion patency at 30 days; 90.9 percent of patients free from revascularization at 6 months EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a ...
Paraneoplastic and symptomatic score for prediction of overall and cancer-specific survival in patients with renal cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results